TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevention of LV adverse remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Portal and hepatic venous enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luminal delivery of 5‐ASA to the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complications after postoperative choledochoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: success of postoperative choledochoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantity of gut lactobacillus and bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of feeding intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: DNR choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician compassion score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Return of sexual function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean IIEF‐5 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile hardness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hospitalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak torque at 60 and 90 degrees per second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lens dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall quality of images
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: signal-to-noise ratios for grey and white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of quadrants affected by PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete regression of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue IV tramadol requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Hypesthesia in mental nerve distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole brain CMRglu
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in social factors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Palliation of chest pain and dyspnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanoma immunoreactivity for histiocytic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-surgical blood transfusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in HH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 90-day death and disability
Endpoint domain: Mortality/survival
Primary endpoint: sICH (symptomatic intracerebral hemorrhage)
Endpoint domain: Adverse events/effects
Primary endpoint: progressively motile sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Durability of the cement mantle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of severe neurodevelopmental disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of other disabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tic severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor outcome risk
Endpoint domain: Mortality/survival
Primary endpoint: unfavorable events
Endpoint domain: Adverse events/effects
Primary endpoint: 90-day major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calcification/ossification evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cortical/marrow involvement evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Exercise work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to complete lung collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of lung collapse score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular and macular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fugl-Meyer Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom stages for upper limb and hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Function Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with no, slight or mild application-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients discontinuing treatment due to application-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Microcomedone count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Alleviation of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma all‐trans RA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Mild Cognitive Impairment (MCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: glycosylated hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PSA recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Cannabis-induced tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak subjective effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental component scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pulsatility index < 1.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in practice for high mortality conditions
Endpoint domain: Mortality/survival
Primary endpoint: PCO rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: augmentation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Caregiver-rated EQ-VAS scores
Endpoint domain: Mortality/survival
Primary endpoint: Clinical remission (Mayo score ≤2, no subscore >1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year RFS rates
Endpoint domain: Mortality/survival
Primary endpoint: Target lesion restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients' belief in dental offices providing TCS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' comfort receiving TCS based on interest in quitting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: BCTQ SYMPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCTQ FUNCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Trait Anxiety Inventory‐State subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of CME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of care opinion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total cancer mortality
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of intestinal carriage with ARGNB at ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acquisition rate of ARGNB after ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: acceptable safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Disability rate at 30-day follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: disc hemorrhage detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: u-AQP2(CR) response to saline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: u-ENaC(β-CR) response to saline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of antibiotics in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological well-being (PGWBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Edinburgh Postnatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Atrioventricular block (AVB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean blood pressure (MBP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction >50% of baseline HAM-D score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUSH tool scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Myocardial infarction incidence
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac events during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Transient ST segment abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total and LDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL-C/HDL-C and ApoB/ApoA-I ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient satisfaction with overall facial appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum sclerostin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Liver histology grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrosis progression rate (FPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Percentages of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fluid challenges necessary for SV optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients needing ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of respiratory disorders in newborn infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of prediabetes
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of smoking among female medical students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior capsule opacification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of ropivacaine administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numeric pain rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute functional orthopedic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnoea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight of RBC units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of RBC units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of RBC use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum pharmacokinetics (PKs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plasma concentrations of oseltamivir and OC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Constant‐Murley score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful outcome in patients' global assessment of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients choosing to undergo surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Insulin secretion at 5 mm glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serous concentration of insulin post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: volume of residual liquid with a low pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction of unpleasant feelings (thirst, hunger, nervousness, fear)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 5-year event free survival (EFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: levels of sTNFR1 and sTNFR2 in ELF samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of fast progressive sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Agreement between SPT results for local and imported allergen extracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient for cat allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gastric contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: suicidal ideation scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rP50 gating improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dP50 gating improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S2P50 amplitudes reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable total NNAL in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of eyelash growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of skin pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of skin hypertrichosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survival curves
Endpoint domain: Mortality/survival
Primary endpoint: 24-h mean heart rate (mHR) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved renal function (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Simulated driving performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant choice of education method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of adverse events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: post-operative drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of routine questions about smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Advice to stop smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reminders about Pap smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased serum liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjunctival staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of the gag reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VC2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of VT/VF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hearing threshold changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of the air-bone gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of inflammatory factors (IL‐1β, IL‐6, TNF‐α, NF‐κB, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression levels of T‐lymphocyte subgroups (CD3+, CD4+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of exfoliated malignant cells at anastomotic sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postoperative analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early convalescence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12 hour urinary cortisol output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage erection fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: permanent study drug withdrawal due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: PBMC membrane fluidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-2R expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of eyelid swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from AF/AT/symptoms
Endpoint domain: Mortality/survival
Primary endpoint: Gene expression of mitochondrial function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalent neurocognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sustained prevalent impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of total streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: amelioration of mastoid cavity aeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Composite of death, Q‐wave myocardial infarction, and large reversible thallium defect
Endpoint domain: Mortality/survival
Primary endpoint: Posture quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qing Deficiency Assessment Scale (QDAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Variability (HRV) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude decline of MMN types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of frequency and intensity MMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes